Krystal Biotech reports news on its commercial genetic-medicines business, led by VYJUVEK, a redosable gene therapy approved in the United States, Europe, and Japan for dystrophic epidermolysis bullosa. Company updates commonly cover VYJUVEK revenue and global commercialization, manufacturing and platform developments, and regulatory actions tied to its HSV-1-based gene delivery technology.
Recurring clinical and scientific updates address investigational programs including KB407 for cystic fibrosis, KB707 for advanced or metastatic non-small cell lung cancer, KB111 for Hailey-Hailey disease, KB803 for corneal abrasions in DEB patients, and additional HSV-1-based vectors. News also includes quarterly operating results, conference presentations, FDA designations, and investor-event participation.
Krystal Biotech (Nasdaq: KRYS) has announced an underwritten public offering of its common stock, granting underwriters a 30-day option for an additional 15% of shares. The offering is subject to market conditions and lacks definitive terms. Proceeds will fund the Phase 3 trial of KB103, advance KB105 development, and support clinical efforts for multiple other compounds. The company seeks to establish a certified manufacturing facility for its products and cover working capital needs. This offering is part of a shelf registration effective since May 4, 2020.
Krystal Biotech announced interim results from a Phase 1/2 clinical trial for KB105, targeting autosomal recessive congenital ichthyosis (ARCI). The treatment was well tolerated in three adult patients, with no adverse events reported. Notably, KB105 showed detectable TGM-1 expression in treated areas, indicating functional activity and reduced disease phenotype reversion. A Phase 2 study in pediatric patients is expected to begin in late 2020, aiming to further validate effectiveness using a new severity score scale.